Abstract:Background: MicroRNA-106b (miR-106b) is thought to be an oncogenic microRNA that promotes tumor growth and metastasis. The potential predictive value of miR-106b was studied in colonic cancer patients. Methods: The expression of miR-106b was examined in 180 colonic cancer cases using in situ hybridization (ISH) technique and was evaluated semi-quantitatively by examining the staining index. The Correlation of miR-106b expression and clinic-pathological features was analyzed by Spearman Rank Correlation. Wilcoxon signed rank test was used for assessing the expression difference of miRNA-106b between colonic cancerous and para-cancerous ones, and their effects on patient survival were analyzed by a log-rank test and the Kaplan-Meier method. Results: MiR-106b was higher expressed in para-cancerous tissues, compared with colonic cancerous ones (P < 0.001). A positive correlation of miR-106b levels between colonic and para-cancerous tissues was also observed (CC = 0.523, P < 0.001). Furthermore, the expression of miR-106b was not significantly correlated with clinic-pathological parameters, including gender, age, histological grade, tumor size, pT stage, pN stage, pM stage and pTNM stage of the patients. Histological grade was positively correlated with pT stage (P = 0.011), pN stage (P = 0.036) and pTNM stage (P = 0.009). Patients expressing high levels of miR-106b both in colonic cancer tissues and para-cancerous ones have a relatively longer survival time but the difference is not statistically significant (P = 0.16). Conclusions: The expression difference of miR-106b levels between colonic tissues and para-cancerous tissues is statistically significant, but the miR-106b levels were not quite correlated with clinic-pathological characteristics and overall survival times of patients with colonic cancer. Lower levels of miR-106b may be connected with neoplastic effects due to interference with TGF-beta signaling, providing evidence that down-regulation of miR-106b might also play an important role in the progression of the disease. The study results are consistent with the literature and support the notion that miR-106b is an oncogenic microRNA.

MiR-106a is an Independent Prognostic Marker in Patients with Glioblastoma.

Analysis of Hsa-Mir-30a-5p Expression in Human Gliomas

In Situ Hybridization Analysis of the Expression of Mir-106B in Colonic Cancer.

Upregulation Of Mir-196b Confers A Poor Prognosis In Glioblastoma Patients Via Inducing A Proliferative Phenotype

Decreased Expression of Microrna-107 Predicts Poorer Prognosis in Glioma

MiR-106a Inhibits Glioma Cell Growth by Targeting E2F1 Independent of P53 Status.

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis.

Low Serum Level of Mir-485-3p Predicts Poor Survival in Patients with Glioblastoma.

Down-regulation of miR-106b suppresses the growth of human glioma cells

Identification of Differentially Expressed Micrornas and the Potential of Microrna-455-3p As a Novel Prognostic Biomarker in Glioma

MicroRNA Signatures Predict Prognosis of Patients with Glioblastoma Multiforme Through the Cancer Genome Atlas.

Mir-182 As a Prognostic Marker for Glioma Progression and Patient Survival

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Diagnostic and prognostic value of miR-106a in colorectal cancer

MiR-196a Exerts Its Oncogenic Effect in Glioblastoma Multiforme by Inhibition of IκBα Both in Vitro and in Vivo.

Correlation of microRNA-10b upregulation and poor prognosis in human gliomas

MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma.

MicroRNA-106b-5p Boosts Glioma Tumorigensis by Targeting Multiple Tumor Suppressor Genes

Identification of an 8-Mirna Signature As a Potential Prognostic Biomarker for Glioma

Mir-200B As a Prognostic Factor Targets Multiple Members of RAB Family in Glioma